GREENWICH, CT and HOUSTON, TX – January 25, 2019 – Great Point Partners, LLC (“Great Point”), a Greenwich-based private investment firm focused on the health care industry, announces today that its portfolio company and strategic partner MaSTherCell Global, Inc. (“MaSTherCell Global”) achieved its first financial milestone targets and as a result Great Point has funded $6.6 million of growth equity to the company’s balance sheet.
In combination with the equity funding, MaSTherCell Global announced that it is expanding into the United States and has executed a lease agreement on a new 30,000 square foot manufacturing facility in Houston, Texas. MaSTherCell Global is a leading cell and gene therapy Contract Development and Manufacturing Organization (“CDMO”) that will now have manufacturing facilities across three continents (US, Europe and Asia). The new facility buildout will be funded with proceeds from Great Point’s growth equity investment.
The Houston facility will have nine manufacturing cleanrooms and multiple process development suites. MaSTherCell Global will now have more than twenty-five cleanrooms across its global manufacturing footprint, with the ability to serve clients on both a clinical and commercial scale.
“Great Point’s additional equity investment will drive growth in the US, Europe, and Korea. GPP continues to support the business with capital and strategic expertise” stated Vered Caplan, Executive Chairman of the Board at MaSTherCell Global.
Noah Rhodes, Managing Director at Great Point Partners, stated “We are thrilled with MaSTherCell Global’s performance since our investment last year. We will continue to support the company with capital to further accelerate its growth and global expansion.”
About Great Point Partners
Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.4 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has committed capital of $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III with a target of $250 million in committed capital) and public (BioMedical Value Fund strategy, approximately $800 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.
Download the press release!